VYNE Therapeutics Inc.

VYNE

NASDAQ

Healthcare

Biotechnology

Bridgewater, NJ, US13 employeesvynetherapeutics.com

$0.61

+0.00(0.58%)

Mkt Cap $10M

$0.29

$1.88

52-Week Range

At a Glance

AI-generated

VYNE Therapeutics Inc.

Revenue breakdown: Royalty (100%).

8-K

VYNE Therapeutics Inc. filed an 8-K on March 11, 2026, providing notice of delisting or failure to satisfy a continued listing rule or standard, as previously disclosed in a prior Current Report on Form 8-K. Specific details of the delisting event were not provided in this filing.

$10M

Market Cap

$222.1K

Revenue

-$10M

Net Income

Employees13

Fundamentals

How The Business Makes Money

Revenue by Segment

Royalty100%($1M)

Activity

What Changed Recently

Delisting

Mar 10, 2026

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed in a Current Report on Form 8-K fil

Material Agreement

Jan 29, 2026

shall have the meanings ascribed to such terms in the Merger Agreement. The Amendment provides that VYNE may provide certain pre-funded warrants (the “Pre-Funde

Peer Companies

Company	Price	Change	Market Cap	P/E
SNGXSoligenix, Inc.	$1.14	-0.87%	$11M	-0.5
BCLIBrainstorm Cell Therapeut...	$0.82	-2.37%	$9M	-0.9
TCRTAlaunos Therapeutics, Inc...	$2.93	-0.68%	$7M	-1.7
KTTAPasithea Therapeutics Cor...	$0.77	+3.49%	$6M	-0.4
QNRXQuoin Pharmaceuticals, Lt...	$6.96	+14.85%	$4M	-0.3
KALAKALA BIO, Inc.	$0.17	+4.11%	$4M	-0.0
MTNBMatinas BioPharma Holding...	$0.55	-0.64%	$3M	—
AIMAIM ImmunoTech Inc.	$0.60	+9.05%	$2M	—

Analyst View

Company Profile

CIK0001566044

ISINUS92941V3087

CUSIP92941V209

Phone800 775 7936

Address520 U.S. Highway 22, Bridgewater, NJ, 08807, US

SEC EDGAR